[en] Background: Parathyroid carcinoma (PCa) is a rare disease that can be difficult to differentiate initially from severe benign parathyroid adenoma. PCa oversecrete the amino form of PTH, which is recognized by third-generation but not by second-generation PTH immunoassays. In normal individuals, the third-generation to second-generation PTH ratio should be less than 1.
Objective: Our objective was to study the utility of the third-generation to second-generation PTH ratio as a means of distinguishing PCa patients (n = 24) from control groups with and without disorders of calcium secretion, including patients on renal hemodialysis (n = 74), postrenal transplantation (n = 60), and primary hyperparathyroidism (PHP; n = 30).
Setting and Design: We conducted a retrospective, laboratory-based study at tertiary referral academic centers.
Results: The mean third-generation to second-generation ratio was 0.58 ± 0.10 in the dialysis patients, 0.54 ± 0.10 in the renal transplant group, 0.54 ± 0.12 in the elderly healthy patients, and 0.68 ± 0.11 in the PHP group. All 245 of these patients presented a PTH third-generation to second-generation ratio of less than 1. In contrast, we observed an inverted third-generation to second-generation PTH ratio of more than one in 20 PCa patients, whereas only four PCa patients had a normal ratio of less than 1.
Conclusions: An inverted third-generation to second-generation PTH ratio occurred in the majority of patients with advanced PCa and was absent in all 245 relevant controls. A third-generation to second-generation PTH ratio higher than 1 had a sensitivity of 83.3% and a specificity of 100% among PHP patients as a marker for PCa. This ratio may be useful to identify patients with PCa earlier and to detect patients either at risk of developing PCa or those in whom recurrence is taking place.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Cavalier, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Betea, Daniela ; Centre Hospitalier Universitaire de Liège - CHU > Endocrinologie clinique
Pruteanu-Apetrii, P. N.
Delanaye, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Stubbs, P.
Bradwell, A. R.
Chapelle, Jean-Paul ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Language :
English
Title :
The Ratio of Parathyroid Hormone as Measured by Third- and Second-Generation Assays as a Marker for Parathyroid Carcinoma.
Publication date :
August 2010
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Thompson SD, Prichard AJ 2004 The management of parathyroid carcinoma. Curr Opin Otolaryngol Head Neck Surg 12:93-97
Shane E 2001 Parathyroid carcinoma. J Clin Endocrinol Metab 86:485-493
Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1999 Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86:538-544
Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP 2008 Parathyroid carcinoma. J Bone Miner Res 23:1869-1880
Grimelius L, Johansson H 1997 Pathology of parathyroid tumors. Semin Surg Oncol 13:142-154
Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P 1998 A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805-809
Quarles LD, Lobaugh B, Murphy G 1992 Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145-150
Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y 1995 Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26:836-844
John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H 1999 A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287-4290
D'Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T 2003 Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 49:2037-2044
Rubin MR, Silverberg SJ, D'Amour P, Brossard JH, Rousseau L, Sliney Jr J, Cantor T, Bilezikian JP 2007 An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1-84) is overproduced in parathyroid carcinoma. Clin Chem 53:1470-1476
Caron P, Maiza JC, Renaud C, Cormier C, Barres BH, Souberbielle JC 2009 High 3rd generation/2nd generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of 3rd generation/2 nd generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 70:533-538
Rakel A, Brossard JH, Patenaude JV, Albert C, Nassif E, Cantor T, Rousseau L, D'Amour P 2005 Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol (Oxf) 62:721-727
Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, Ghaye B, Daly AF, Beckers A 2004 Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 89:3413-3420
Bradwell AR, Harvey TC 1999 Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 353:370-373
Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A 2000 A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753-761
Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P 2001 Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142:1386-1392
Divieti P, John MR, Jüppner H, Bringhurst FR 2002 Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143:171-176
Divieti P, Geller AI, Suliman G, Jüppner H, Bringhurst FR 2005 Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: determinants of ligand binding and bioactivity. Endocrinology 146:1863-1870
Blachowicz A, Chudzinski W, Nawrot I, Kryszalowicz B, Spiechowicz U, Szmidt J, Wiecek A, Franek E 2008 Serum 1-84 and 7-84 parathyroid hormone concentrations and bone in patients with primary hyperparathyroidism. Langenbecks Arch Surg 393:709-713